Yahoo Finance8d
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
(“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions ...
Nasdaq9d
AIM ImmunoTech Inc. Highlights Study Linking COVID-19 to Increased Risk of ME/CFS and Ampligen's Potential as a Therapeutic Solution
A study links COVID-19 infection to higher ME/CFS rates, supporting Ampligen's potential as a treatment for affected individuals. AIM ImmunoTech Inc. has commented on a recently published study in ...